ライフサイエンスコーパス: osteoporotic fracture

1 % for hip fracture or at least 20% for major osteoporotic fracture.

2 strong diagnostic value for osteoporosis and osteoporotic fracture.

3 a means to improve bone strength and reduce osteoporotic fracture.

4 oteins increase the risk of osteoporosis and osteoporotic fracture.

5 Vertebral fractures are the most common osteoporotic fracture.

6 d bone mineral density and increased risk of osteoporotic fracture.

7 to maximize efficacy in patients at risk for osteoporotic fracture.

8 ross-linking, thereby increasing the risk of osteoporotic fracture.

9 ed to low bone density and increased risk of osteoporotic fracture.

10 , bone mineral density, and the incidence of osteoporotic fracture.

11 functioning and thus may reduce the risk for osteoporotic fracture.

12 ement bone densitometry in assessing risk of osteoporotic fracture.

13 at is significantly related to bone mass and osteoporotic fracture.

14 A secondary outcome was major osteoporotic fracture.

15 ity (BMD) is a highly heritable predictor of osteoporotic fracture.

16 ated with decreased BMD or increased risk of osteoporotic fracture.

17 fragility fracture, any fracture, and major osteoporotic fracture.

18 eatment in persons at high risk following an osteoporotic fracture.

19 lomipramine (CLP), have an increased risk of osteoporotic fracture.

20 ty and an increased risk of fracture, termed osteoporotic fracture.

21 ccurately identify those at greatest risk of osteoporotic fracture.

22 nd may remain an option in the prevention of osteoporotic fracture.

23 The primary endpoint was time to first osteoporotic fracture.

24 rs) after cohort entry for an incident major osteoporotic fracture.

25 ral density (BMD) predicts the likelihood of osteoporotic fracture.

26 up, 21 (4.6%) recipients experienced a major osteoporotic fracture.

27 ure and 113 participants experienced a major osteoporotic fracture.

28 fully improve the prediction of hip or major osteoporotic fracture.

29 increased fracture risk, particularly major osteoporotic fractures.

30 core for presymptomatic prediction of future osteoporotic fractures.

31 1 older US women from the Caregiver-Study of Osteoporotic Fractures.

32 and April 2004 in a substudy of the Study of Osteoporotic Fractures.

33 eric femur that are infrequently affected by osteoporotic fractures.

34 d the exercise type most effective to reduce osteoporotic fractures.

35 tive was to examine FA intake in relation to osteoporotic fractures.

36 wered hip BMD but did not change the risk of osteoporotic fractures.

37 tate cancer is associated with bone loss and osteoporotic fractures.

38 ars of age who were enrolled in the Study of Osteoporotic Fractures.

39 independent risk factor for osteoporosis and osteoporotic fractures.

40 Patients with RA are at increased risk of osteoporotic fractures.

41 or =65 years of age enrolled in the Study of Osteoporotic Fractures.

42 of the hip in elderly women in the Study of Osteoporotic Fractures.

43 at the baseline examination of the Study of Osteoporotic Fractures.

44 at the baseline examination of the Study of Osteoporotic Fractures.

45 rly women are associated with a reduction in osteoporotic fractures.

46 uman beings and thereby decrease the risk of osteoporotic fractures.

47 es may be consistent with a reduction in all osteoporotic fractures.

48 at 26 million American women are at risk for osteoporotic fractures.

49 od most often used to determine the risk for osteoporotic fractures.

50 of sex and racial differences in the risk of osteoporotic fractures.

51 of age or older and enrolled in the Study of Osteoporotic Fractures.

52 porotic Fractures in Men Study, and Study of Osteoporotic Fractures.

53 of the COVID-19 pandemic on the incidence of osteoporotic fractures.

54 d in some patients with ET or PV can lead to osteoporotic fractures.

55 oid prescriptions had similar rates of major osteoporotic fractures.

56 e globe are facing a substantial increase in osteoporotic fractures.

57 l anticoagulant (OAC) may affect the risk of osteoporotic fractures.

58 om bisphosphonate-treated women with typical osteoporotic fractures.

59 t been systematically studied in relation to osteoporotic fractures.

60 gnificant gene BDNF was also associated with osteoporotic fractures.

61 hosphonates are a common treatment to reduce osteoporotic fractures.

62 c kidney disease, chronic liver disease, and osteoporotic fractures.

63 n is the root cause for bone loss leading to osteoporotic fractures.

64 Ps in the setting of secondary prevention of osteoporotic fractures.

65 ysteine concentrations are a risk factor for osteoporotic fractures.

66 osphonates are effective in reducing hip and osteoporotic fractures.

67 but also to contribute to the development of osteoporotic fractures.

68 frican-American participants in the Study of Osteoporotic Fractures.

69 associated with a 4-fold increased risk for osteoporotic fractures.

70 hniques should be used to diagnose prevalent osteoporotic fractures.

71 , and low risk of fractures [HR (95% CI) for osteoporotic fractures: 0.90 (0.83, 0.96); for hip fract

72 and high risk of fractures [HR (95% CI) for osteoporotic fractures: 1.08 (1.00, 1.06); for hip fract

73 Osteoporotic fracture (11.9%) was also more common in cl

74 13 239 individuals (14.6%), including 12 425 osteoporotic fractures (14.0%), 9440 major osteoporotic

75 52 patients were reviewed (121 patients with osteoporotic fractures, 30 with malignant disease, and o

76 Following an osteoporotic fracture, a multidisciplinary rehabilitatio

77 ls, among 6,653 participants in the Study of Osteoporotic Fractures, a community-based, prospective c

78 linical centers and enrolled in the Study of Osteoporotic Fractures, a longitudinal cohort study.

79 The Study of Osteoporotic Fractures, a prospective cohort study of wh

80 ere vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse eve

81 did not have a significantly reduced risk of osteoporotic fracture, although there was a trend toward

82 mitigating bone loss and in reducing risk of osteoporotic fractures among older adults.

83 The decreased risks seen for osteoporotic fracture and colorectal cancer were outweig

84 treatment, including reductions in risks of osteoporotic fracture and coronary heart disease, and th

85 ted whether MI constitutes a risk factor for osteoporotic fracture and examined secular trends in thi

86 erved for higher intake of flavonols for any osteoporotic fracture and major osteoporotic fracture, a

87 xists between individuals who are at risk of osteoporotic fracture and those who are receiving therap

88 amined magnesium intake as a risk factor for osteoporotic fractures and altered bone mineral density

89 Benefits of HRT include prevention of osteoporotic fractures and colorectal cancer, while prev

90 (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and ne

91 Osteoporotic fractures and osteoporosis were found in 37

92 inty); and thiazolidinediones increase major osteoporotic fractures and probably increase hospitalisa

93 e-related disorder leading to an increase in osteoporotic fractures and resulting in significant suff

94 T to assess performance for predicting major osteoporotic fractures and to compare with the Fracture

95 reening and fracture (any fracture and major osteoporotic fracture) and overall survival were calcula

96 vity, prolonged corticosteroid use, previous osteoporotic fracture, and androgen deprivation therapy.

97 omen; 212 (17.8%) were identified as a major osteoporotic fracture, and of these, 129 (10.9%) were a

98 0-60% in persons with low bone mass or prior osteoporotic fracture, and SREs by one-third in cancer p

99 ncer risk factors, clinical risk factors for osteoporotic fractures, and bone mineral density surveil

100 D) is highly heritable, a major predictor of osteoporotic fractures, and has been previously associat

101 elderly white women enrolled in the Study of Osteoporotic Fractures, and initial breast cancer status

102 ed hazard ratios for all incident fractures, osteoporotic fractures, and MOFs, according to age at fi

103 Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteo

104 Traits contributing to osteoporotic fracture are highly heritable, indicating t

105 ably, bone mineral density, osteoporosis and osteoporotic fracture are highly heritable; however, det

106 Osteoporotic fractures are a leading cause of disability

107 Osteoporotic fractures are associated with psychological

108 Although methods to identify risk for osteoporotic fractures are available and medications to

109 Osteoporotic fractures are common among elderly men.

110 of the use of cimetidine on osteoporosis and osteoporotic fractures are indicated.

111 at BPs dispensed for secondary prevention of osteoporotic fractures are not associated with increased

112 an 65 years who are at increased risk for an osteoporotic fracture as estimated by clinical risk asse

113 uggested slightly greater efficacy for major osteoporotic fractures (as an exploratory end point) for

114 nols for any osteoporotic fracture and major osteoporotic fracture, as well as flavones for hip fract

115 This study [B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF)] aimed to determine whe

116 Furthermore, paraffin sections of human osteoporotic fractured bone exhibited increased RANKL im

117 ted proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs dire

118 Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety

119 ctures, which are an indicator of subsequent osteoporotic fractures, can be identified using dual-ene

120 d of sound (SOS)-a heritable risk factor for osteoporotic fracture-can identify low-risk individuals

121 an age = 79 years) in the Caregiver-Study of Osteoporotic Fractures (Caregiver-SOF) (1999-2009), an a

122 an women, age >/=65 years, from the Study of Osteoporotic Fractures cohort was performed.

123 min K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background popu

124 ssociated with a significantly lower risk of osteoporotic fractures compared with VKA.

125 with adjudicated fracture outcomes (Study of Osteoporotic Fractures [December 1998-July 2008]; Osteop

126 rea under the curve (AUC) for incident major osteoporotic fracture discrimination (AUC: FRAX with BMD

127 with nonmetastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to t

128 mineral density (BMD) and increased risk of osteoporotic fracture, especially in older postmenopausa

129 thologic fractures are associated with major osteoporotic fracture events in women with invasive brea

130 The Study of Osteoporotic Fractures followed up 8022 women for 9.1 ye

131 ars or older, who have been hospitalized for osteoporotic fracture from 2003 until 2005.

132 udies, the Beijing OA Study and the Study of Osteoporotic Fractures from the US.

133 creen use), site-specific and total BMD, and osteoporotic fractures (hip, wrist, and spine) in the NH

134 THR patients who had experienced a previous osteoporotic fracture (HR 0.48, 95% CI 0.23-0.99).

135 ratio [HR], 0.43 [95% CI, 0.41-0.44]), major osteoporotic fracture (HR, 0.32 [95% CI, 0.31-0.33]), an

136 [HR], 1.43 [95% CI, 1.16 to 1.78]) and major osteoporotic fracture (HR, 1.21 [95% CI, 1.01 to 1.45])

137 the highest tertile had a lower risk of any osteoporotic fracture (HR: 0.65; 95% CI: 0.47, 0.88), ma

138 acture (HR: 0.65; 95% CI: 0.47, 0.88), major osteoporotic fracture (HR: 0.66; 95% CI: 0.45, 0.95), an

139 iated with a 30% decrease in the risk of any osteoporotic fracture (HR: 0.70; 95% CI: 0.50, 0.96).

140 tio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99),

141 to LMWH) in 0.11% (95% CI, 0.02%-0.32%), and osteoporotic fracture in 0.04% (95% CI, < 0.01%-0.20%) o

142 ncreasing evidence suggests that the risk of osteoporotic fracture in adulthood could be determined p

143 risk factors for low bone mineral density or osteoporotic fracture in men or comparing 2 different me

144 eveloping strategies to reduce the burden of osteoporotic fracture in the population.

145 ead to longlasting reductions in the risk of osteoporotic fracture in their offspring.

146 ce in transfer are significant predictors of osteoporotic fracture in white female nursing home resid

147 1.6 years), with documented subsequent major osteoporotic fractures in 7.4% (n = 686), including hip

148 The aims are to establish the prevalence of osteoporotic fractures in ISM and to investigate the ass

149 ncluded 517 men who were participants in the Osteoporotic Fractures in Men (MrOS) Study (>=65 y of ag

150 ation-based age-specific fracture rates; the Osteoporotic Fractures in Men (MrOS) study and published

151 n Older Men Study (an ancillary study to the Osteoporotic Fractures in Men (MrOS) Study conducted in

152 The Osteoporotic Fractures in Men (MrOS) study is the first

153 s); Invecchiare in Chianti (n = 873, Italy); Osteoporotic Fractures in Men (n = 2301, United States);

154 ms for screening for osteoporosis to prevent osteoporotic fractures in men cannot be determined.

155 overnight polysomnograms of 2782 men in the Osteoporotic Fractures in Men Study (MrOS) Sleep study,

156 The genomic and phenotypic data of Osteoporotic Fractures in Men Study (n = 5130) was analy

157 porotic Fractures [December 1998-July 2008]; Osteoporotic Fractures in Men Study [March 2000-March 20

158 The Osteoporotic Fractures in Men Study followed up 5995 men

159 d DHEA-S in the prospective population-based Osteoporotic Fractures in Men study in Sweden (2,416 men

160 h Study) and 2,193 participants in the MrOS (Osteoporotic Fractures in Men Study) Sleep study.

161 In a cohort of 1,104 elderly men from the Osteoporotic Fractures in Men Study, 25(OH)D serum level

162 sical performance with incident falls in the Osteoporotic Fractures in Men Study, a large prospective

163 study of 2,865 participants derived from the Osteoporotic Fractures in Men Study, a prospective multi

164 Health Study, Framingham Heart Study (FHS), Osteoporotic Fractures in Men Study, and Study of Osteop

165 >/=65 years of age who were enrolled in the Osteoporotic Fractures in Men Study.

166 Participants were recruited from the Osteoporotic Fractures in Men Study.

167 rms of screening for osteoporosis to prevent osteoporotic fractures in men.

168 mmends screening for osteoporosis to prevent osteoporotic fractures in postmenopausal women younger t

169 y that screening for osteoporosis to prevent osteoporotic fractures in postmenopausal women younger t

170 to osteoporosis and to estimate the risk of osteoporotic fractures in relation to body weight, lean

171 The number of osteoporotic fractures in the groups was similar.

172 5 men older than 50 years of age experience osteoporotic fractures in their lifetime.

173 Participants in the Study of Osteoporotic Fractures in whom pelvic radiographs had be

174 y that screening for osteoporosis to prevent osteoporotic fractures in women 65 years or older has mo

175 mmends screening for osteoporosis to prevent osteoporotic fractures in women 65 years or older.

176 B-12 and folic acid supplementation reduces osteoporotic fracture incidence in hyperhomocysteinemic

177 folic acid supplementation had no effect on osteoporotic fracture incidence in this elderly populati

178 ach of the studies and at each major site of osteoporotic fracture, including the hip and wrist.

179 past decades, the association between MI and osteoporotic fractures increased steadily.

180 assessed at the baseline Caregiver-Study of Osteoporotic Fractures interview, conducted in 1999-2001

181 Osteoporotic fracture is a significant source of morbidi

182 Osteoporotic fracture is among the most common and costl

183 in patients with ISM shows that the risk of osteoporotic fractures is high, especially in men.

184 Protection against osteoporotic fractures is supported by a meta-analysis o

185 ssary component of bone, but its relation to osteoporotic fractures is unclear.

186 ing health outcomes, including prevention of osteoporotic fractures, is essential for promoting the w

187 However, risk of osteoporosis and major osteoporotic fracture (MOF) after application of topical

188 iction tool for 10-year probability of major osteoporotic fracture (MOF) and hip fracture in the gene

189 FRAX scores for major osteoporotic fracture (MOF) and hip fracture were calcul

190 years) with 10 years of follow-up for major osteoporotic fracture (MOF; including hip, clinical spin

191 4) years, 1071 incident fractures, 853 major osteoporotic fractures (MOF), and 232 hip fractures occu

192 5 osteoporotic fractures (14.0%), 9440 major osteoporotic fractures (MOFs) (10.6%), and 3068 hip frac

193 Incident nontraumatic major osteoporotic fractures (MOFs) and hip fractures.

194 Men (n = 2301, United States); and Study of Osteoporotic Fractures (n = 5862, United States)-we asse

195 Falls are the chief mechanism by which osteoporotic fractures occur.

196 Many individuals are not diagnosed until osteoporotic fractures occur.

197 A total of 223 osteoporotic fractures occurred among 180 women.

198 Osteoporotic fractures occurred in 61 persons (4.2%) in

199 Documented osteoporotic fracture occurring during follow-up as a fu

200 me fracture (occurring after age 13 y) or an osteoporotic fracture (occurring after age 50 y).

201 femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1.3, 95% CI 1.09

202 Only osteoporotic fractures of the hip, vertebrae, and wrist

203 n descent can help improve the prediction of osteoporotic fracture (OF) risk and BMD in Chinese popul

204 nts registered with diagnostic codes for non-osteoporotic fractures or hip or knee replacement becaus

205 e of both risk alleles increased the risk of osteoporotic fractures (OR 1.3, 1.08-1.63, p=0.006) and

206 Outcome measures were time to osteoporotic fracture, overall and by anatomic site, and

207 study population was drawn from the Study of Osteoporotic Fractures, Pittsburgh, Pennsylvania, during

208 with a modest decrease in the prevalence of osteoporotic fractures, possibly owing to risk-averse be

209 Osteoporotic fractures present a significant social and

210 Although osteoporotic fractures present an enormous health burden

211 roup analyses suggest a beneficial effect on osteoporotic fracture prevention in compliant persons ag

212 kshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available

213 Current treatments for osteoporotic fractures primarily target bone-resorbing o

214 ificantly associated with the development of osteoporotic fractures (relative risk [RR] 2.5, 95% conf

215 Osteoporotic fractures represent an enormous public heal

216 Incidence of osteoporotic fracture requiring hospitalization was dete

217 or modulator) have each been shown to reduce osteoporotic fracture risk among men receiving androgen-

218 drugs available for these diseases, reducing osteoporotic fracture risk by 50-60% in persons with low

219 Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to m

220 concentrations may be associated with lower osteoporotic fracture risk in older adults, particularly

221 sorders and psychotropic medication use with osteoporotic fracture risk in routine clinical practice.

222 The observed 10-year major osteoporotic fracture risk of 6.3% (95% CI, 3.4-9.2%) wa

223 ersons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention

224 Osteoporotic fracture risk was not significantly differe

225 Research shows that optimal screening for osteoporotic fracture risk will require risk factor info

226 hly heritable trait and a key determinant of osteoporotic fracture risk, but the genes responsible ar

227 as a clinical aid to assess an individual's osteoporotic fracture risk, with or without bone mineral

228 bone remodeling associated with an increased osteoporotic fracture risk.

229 proves bone mineral density, a surrogate for osteoporotic fracture risk.

230 e important dietary components that modulate osteoporotic fracture risk.

231 etic component and an important predictor of osteoporotic fracture risk.

232 n in early life, midlife, and late life with osteoporotic fracture risk.

233 n, vitamin D and calcium deficiency increase osteoporotic fracture risk.

234 ociated with a small increase in the risk of osteoporotic fractures (RR 1.3, 95% CI 1.0, 1.8); howeve

235 01 elderly women from the Caregiver-Study of Osteoporotic Fractures sample.

236 men with DM; HRs for 1-unit increase in FRAX osteoporotic fracture score, 1.04; 95% CI, 1.02-1.05, fo

237 Major osteoporotic fracture scores showed significant fracture

238 higher among those with osteomyelitis at all osteoporotic fracture sites after adjusting for key rela

239 MrOS) Sleep study, 424 women in the Study of Osteoporotic Fractures (SOF) and 2221 men and 2574 women

240 women ages > or = 65 years from the Study of Osteoporotic Fractures (SOF) and white men and women age

241 y community-dwelling women from the Study of Osteoporotic Fractures (SOF) cohort (mean age 83 years)

242 The Study of Osteoporotic Fractures (SOF) is a prospective, observati

243 Pittsburgh Clinical Center for the Study of Osteoporotic Fractures (SOF), a prospective cohort study

244 the Pittsburgh Field Center of the Study of Osteoporotic Fractures (SOF), a prospective study of a c

245 99-2009), an ancillary study to the Study of Osteoporotic Fractures (SOF).

246 Given the economic and social costs of osteoporotic fractures, strategies to identify and manag

247 aging needs to be used to diagnose prevalent osteoporotic fractures, such as spine fractures on chest

248 Despite African Americans' reduced risk of osteoporotic fractures, such fractures remain an importa

249 ic patients have a higher risk of sustaining osteoporotic fractures than non-diabetic people.

250 treatment to limit the enormous increase in osteoporotic fractures that has been predicted as the ag

251 five families with X-linked osteoporosis and osteoporotic fractures that we report here.

252 For those patients with substantial risk of osteoporotic fracture, the clinician should obtain a bon

253 In elderly men, who are at greatest risk for osteoporotic fracture, the influence of hypogonadism on

254 that many agents are effective in preventing osteoporotic fractures, the data are insufficient to det

255 Risk of hip or major osteoporotic fracture through 2009 or 12 years following

256 We used data from the prospective Study of Osteoporotic Fractures to estimate risk of fracture from

257 fragility fracture, any fracture, and major osteoporotic fracture was 0.72 (95% CI, 0.55 to 0.93), 0

258 , 0.6-1.4), whereas the relative risk for an osteoporotic fracture was 1.4 (95% CI, 0.7-2.7).

259 Tool score, or FRAX), 10-year risk for major osteoporotic fracture was greater than 20% (FRAX), quant

260 A family history of osteoporotic fracture was strongly associated with low B

261 The risk of osteoporotic fractures was evaluated among patients with

262 The ability to identify patients with osteoporotic fractures was evaluated by using receiver o

263 ort of 5,552 elderly women from the Study of Osteoporotic Fractures was followed up prospectively for

264 nationwide population, the absolute risk of osteoporotic fractures was low among patients with atria

265 Osteoporotic fractures were determined from medical reco

266 Over 10 y of follow-up, osteoporotic fractures were identified in 288 (24.2%) wo

267 We studied 5,839 women from the Study of Osteoporotic Fractures who had had serial pelvic radiogr

268 Reducing osteoporotic fractures will require more effective appro

269 es are the most common clinically recognized osteoporotic fractures with a relatively high heritabili

270 ith AFFs to those from patients with typical osteoporotic fractures with and without bisphosphonate t

271 association between the replicated SNPs and osteoporotic fractures with data from two studies.

272 > or =74 years participating in the Study of Osteoporotic Fractures year 10 follow-up (n = 906) in 19